Neuroblastoma Drugs Market Insights Video

According to Cognitive Market Research, the global NeuroblastomaDrug Market size is USD 721.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 4.20% from 2024 to 2031.

• North America held the major market share for more than 40% of the global revenue with a market size of USD 288.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.4% from 2024 to 2031.
• Europe accounted for a market share of over 30% of the global revenue with a market size of USD 216.45 million.
• Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 165.95 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
• Latin America had a market share for more than 5% of the global revenue with a market size of USD 36.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031.
• Middle East and Africa hada market share of around 2% of the global revenue and was estimated at a market size of USD 14.43 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031.
• The dominant distribution channel is offline. Offline channels, due to the critical nature of the condition requiring direct medical supervision and prescription.